Jeil Pharm (002620) — Cash Flow-to-Debt Ratio
Jeil Pharm (002620) has a Cash Flow-to-Debt Ratio of 0.00x as of March 2026, meaning its operating cash flow of ₩447.08 Million could theoretically repay 0% of its total liabilities (₩403.14 Billion) in one year. See Jeil Pharm (002620) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Jeil Pharm Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Jeil Pharm across 13 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Jeil Pharm.
Annual Cash Flow-to-Debt Ratio for Jeil Pharm (2011–2025)
Year-by-year debt coverage analysis for Jeil Pharm. Check 002620 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.00x | ₩390.26 Million | ₩407.55 Billion | ▼ -90.4% |
| 2024 | 0.01x | ₩4.54 Billion | ₩453.04 Billion | ▲ +208.5% |
| 2023 | -0.01x | ₩-4.42 Billion | ₩477.81 Billion | ▲ +80.2% |
| 2022 | -0.05x | ₩-20.80 Billion | ₩445.88 Billion | ▼ -236.5% |
| 2021 | 0.03x | ₩13.40 Billion | ₩392.11 Billion | ▲ +156.0% |
| 2020 | -0.06x | ₩-23.67 Billion | ₩388.11 Billion | ▼ -187.9% |
| 2019 | 0.07x | ₩25.22 Billion | ₩363.44 Billion | ▲ +768.0% |
| 2018 | -0.01x | ₩-3.43 Billion | ₩330.51 Billion | ▼ -104.8% |
| 2017 | 0.22x | ₩5.92 Billion | ₩27.15 Billion | ▲ +360.9% |
| 2016 | 0.05x | ₩11.36 Billion | ₩239.91 Billion | ▲ +251.6% |
| 2015 | 0.01x | ₩2.74 Billion | ₩203.78 Billion | ▲ +151.0% |
| 2012 | -0.03x | ₩-3.94 Billion | ₩149.36 Billion | ▼ -117.1% |
| 2011 | 0.15x | ₩23.63 Billion | ₩152.74 Billion | — |